A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

PHASE3RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

December 5, 2029

Study Completion Date

December 11, 2029

Conditions
Thrombocytopenia, Neonatal Alloimmune
Interventions
DRUG

Nipocalimab

Nipocalimab will be administered intravenously.

DRUG

Placebo

Placebo will be administered intravenously.

Trial Locations (20)

1000

RECRUITING

Univerzitetni klinicni center Ljubljana, Ljubljana

1011

RECRUITING

Centre Hospitalier Universitaire Vaudois CHUV, Lausanne

1082

RECRUITING

Semmelweis Egyetem, Budapest

3000

RECRUITING

Universitair Ziekenhuis Leuven, Leuven

5009

RECRUITING

Haukeland University Hospital, Bergen

7030

RECRUITING

St. Olavs Hospital, Trondheim

9019

RECRUITING

Universitetssykehuset Nord-Norge HF, Tromsø

41013

RECRUITING

Hosp. Virgen Del Rocio, Seville

59000

RECRUITING

CHRU Lille, Lille

75012

RECRUITING

Hopital trousseau- APHP, Paris

5262000

RECRUITING

Sheba Medical Center, Ramat Gan

50070-902

RECRUITING

Instituto de Medicina Integral Professor Fernando Figueira, Recife

22281 00

RECRUITING

Instituto D Or de Pesquisa e Ensino IDOR, Rio de Janeiro

05403 000

RECRUITING

Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo

00168

RECRUITING

Fondazione Policlinico Universitario A Gemelli IRCCS, Rome

0455

RECRUITING

Oslo University Hospital HF Ulleval sykehus, Oslo

04190

RECRUITING

Univerzitna nemocnica L. Pasteura Kosice, Košice

036 01

RECRUITING

Univerzitná nemocnica Martin, Martin

940 34

RECRUITING

Fakultna nemocnica s poliklinikou Nove Zamky, Nové Zámky

SE-141 86

RECRUITING

Karolinska Universitetssjukhuset Huddinge, Stockholm

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY